NCT07255326Completed
Effect of Omega-3 Fatty Acids on Eye Blood Vessels in Type 1 Diabetes
Role of Omega-3 Fatty Acids in Modulating Retinal Microvascular Changes in Type 1 Diabetes
Source: ClinicalTrials.gov · Last updated 30 Jun 2026
Brief summary (registry, in English)
This double-blind, placebo-controlled randomized clinical trial evaluates the effects of omega-3 fatty acid supplementation on retinal vascular structure and function in children and adolescents with type 1 diabetes. The study compares omega-3 supplementation with placebo to assess changes in retinal microvascular parameters, retinal blood flow, visual function, and systemic biomarkers over time, as well as the safety and tolerability of supplementation during the study period.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 70 (actual)
- First submitted
- 14 Nov 2025
- Start date
- 12 Feb 2025
- Primary completion date
- 30 Jan 2026
- Lead sponsor
- University of Faisalabad
- Diseases
- Type 1 diabetes, Diabetic eye disease
- NCT number
- NCT07255326
What you commit to
- Study type: Interventional
- Participants enrolled: 70
- From 12 Feb 2025 to the primary completion date, 30 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Type 1 Diabetes with earliest changes i.e. microaneurysms or changes in retinal vessels
Age in the registry: 10 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Faisalabad Coordinator of this site? Confirm its status | Faisalābad | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.